Drugs / DTaP-IPV-Hib
DTaP-IPV-Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05951725 Comparator | Aug 2023 → Apr 2025 overdue | — | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07354269 Comparator | Sep 2025 → Apr 2026 overdue | poliomyelitis | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV-Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951725 ↗ |
| Known as | Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib | “Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib” NCT05951725 ↗ |
| Known as | DTaP-IPV-Hib Pentavalent Vaccine | “Phase IV Clinical Study Comparing the Immunogenicity and Safety of a Single-dose Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains (sIPV) in Adolescents and Adults...” NCT07354269 ↗ |
| Modality | Vaccine | “The combined pertussis, diphtheria and tetanus vaccine” NCT05951725 ↗ |
| Route | Intramuscular | “three doses of DTaP-IPV-Hib administered via intramuscular injection following the schedule of 3,4,5 months old” NCT07354269 ↗ |